pegylated liposomes | peg liposomes | liposomes research report

13
RITMIR028: Liposomes A Market Insight Report, July 2013 © RI Technologies - www.researchimpact.com Sample Page - 1 LIPOSOMES MARKET SIZE Scope of the Study This market insight report on Liposomes gives an insight into global Liposomes market. The report provides market analytics by application, and by therapeutic area. The market is divided by Application into Therapeutic, Cosmetic and Other; and by Therapeutics into Antifungal, Anticancer, Ophthalmic and Other. The study also provides information regarding products and technologies in the field of Liposomes. Business profiles of 46 major companies are discussed in the report. The report covers more than 330 companies that are engaged in Liposomes research and supply of products and/or services. Compilation of Worldwide Patents and Research related to Liposomes is also provided. Projections and estimates are also illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World with 97 exclusive graphically represented exhibits. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, and other areas of concern is also covered in the report. Liposomes’ report is an ideal research tool providing strategic business intelligence to the corporate sector. This report may help strategists, investors, laboratories, pharmaceutical companies, contract research organizations, biotechnology companies and drug approval authorities in-- Gauging Competitive Intelligence Identifying Key Growth Areas and Opportunities Understanding Geographic Relevance to Product Knowing Regional Market Sizes and Growth Opportunities and Restraints Keeping Tab on Emerging Technologies Equity Analysis Tapping New Markets Analytics and data presented in this report pertain to several parameters such as Global and Regional Market Sizes, Market Shares, Market Trends Product (Global and Regional) Market Sizes, Market Shares, Market Trends Technology Trends Corporate Intelligence Key Companies by Sales, Brands, Products Consumer Behavioral Patterns

Upload: research-impact

Post on 27-Jan-2015

135 views

Category:

Health & Medicine


7 download

DESCRIPTION

Market report on Liposomes gives an insight into global Liposomes market. The report provides market analytics by application, and by therapeutic area. The market is divided by Application into Therapeutic, Cosmetic and Other; and by Therapeutics into Anti fungal, Anticancer, Ophthalmic and Other. The study also provides information regarding products and technologies in the field of Liposomes. Business profiles of 37 major companies are discussed in the report. The report covers more than 330 companies that are engaged in Liposomes research and supply of products and/or services. Compilation of Worldwide Patents and Research related to Liposomes is also provided. Projections and estimates are also illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World with 114 exclusive graphically represented exhibits. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, and other areas of concern is also covered in the report.

TRANSCRIPT

Page 1: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 1

LIPOSOMES MARKET SIZE

Scope of the Study

This market insight report on Liposomes gives an insight into global Liposomes market. The report provides

market analytics by application, and by therapeutic area. The market is divided by Application into

Therapeutic, Cosmetic and Other; and by Therapeutics into Antifungal, Anticancer, Ophthalmic and Other.

The study also provides information regarding products and technologies in the field of Liposomes.

Business profiles of 46 major companies are discussed in the report. The report covers more than 330

companies that are engaged in Liposomes research and supply of products and/or services. Compilation of

Worldwide Patents and Research related to Liposomes is also provided. Projections and estimates are also

illustrated by geographic regions encompassing North America, Europe, Asia-Pacific, and Rest of World with

97 exclusive graphically represented exhibits. Information related to recent product releases, product

developments, partnerships, collaborations, mergers and acquisitions, and other areas of concern is also

covered in the report.

Liposomes’ report is an ideal research tool providing strategic business intelligence to the corporate sector.

This report may help strategists, investors, laboratories, pharmaceutical companies, contract research

organizations, biotechnology companies and drug approval authorities in--

Gauging Competitive Intelligence

Identifying Key Growth Areas and Opportunities

Understanding Geographic Relevance to Product

Knowing Regional Market Sizes and Growth Opportunities and Restraints

Keeping Tab on Emerging Technologies

Equity Analysis

Tapping New Markets

Analytics and data presented in this report pertain to several parameters such as –

Global and Regional Market Sizes, Market Shares, Market Trends

Product (Global and Regional) Market Sizes, Market Shares, Market Trends

Technology Trends

Corporate Intelligence

Key Companies by Sales, Brands, Products

Consumer Behavioral Patterns

Page 2: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 2

Other Strategic Business Affecting Data

Research Methodology

RI Technologies publishes business intelligence reports by going through a cycle of diligent research and

analysis activity. Research is done using both online and offline resources. The study outline of this report is

sketched on the following lines – global market analysis, regional market analysis, product segmentation,

global and regional market analysis by product segment, market trends, M&A, R&D, competitive landscape,

technology trends, and other key drivers. Current data helps in analyzing the future of the industry and is

also helpful for doing market evaluations, and estimating the market size for the future.

This report is uniquely researched and the methodology includes:

Need and Scope of Study

Product Definitions

Segmental Analysis

Regional Analysis

Exclusive Data Analytics

Corporate Intelligence

Feedback

Right from concept to final compilation of this report, both primary and secondary research methods are

applied. We have provided exclusive feedback forms/pre-release questionnaires for this report to use the

information for authentication of our own findings. Secondary research includes government publications,

investment research reports, web based surveys, website information of both companies and markets, and

other offline resources such as print publications and CDs.

Our compilation of easy to navigate PDF reports are essential value addition resources for leading and

growing companies.

Page 3: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 3

II - REPORT SYNOPSIS

Liposomes are nano sized artificial vesicles of spherical shape composed of a bilayer membrane that can be

produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived

phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain

a core of aqueous material; lipid spheres that contain no aqueous material are called micelles,

The size of these spheres is very small, in the order of a nanometer. Because of the small size of the

phospholipid molecule and microspheres, they can pass through the epidermis and act as a carrier for the

enclosed substances.

Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or

even a gene. Liposomes are capable of entering the body without causing an immune rejection or

hypersensitivity reaction.

Segmentation of Liposomes Market

Exhibit 1. Segmentation of Global Liposomes Market by Application

Application

Therapeutic

Cosmetic

Other*

© RIT, 2013

* Includes Agro-Food, Paints (Water Based, Resins, Self Healing Paints),

Neutraceuticals, and Diagnostics

Liposomal Formulations Used in Medical Practice

Liposomes belong to the class of nanosized unilamellar phospholipid bilayer vesicles. These are considered

as the most promising and comprehensively studied drug delivery vehicles. The applications of the

Liposome-formulated drugs have enhanced over the years and they are now part of the cancer treatment

and systemic or local fungal infections. The unique feature of the Liposome-formulated drugs to remain

biologically inert, biocompatible and restricting the cause of unwanted toxic or antigenic reactions have

helped it maintain a high level of popularity in the field of drug research. The horizon and application of

Liposomes have enormously undergone transformations owing to its use in the treatment of solid tumors.

The tumors are targetted with Liposomes containing bisphosphonate which reduces the tumor associated

macrophages. The Other important developments like use of genetic components as therapeutic molecules

are the advancements in the field of delivery systems have further enhanced the scope of Liposomes based

therapy. The components of Liposomes present in the lipid-DNA complexes commonly called lipoplexes,

combat with the viral gene transfection systems. The excellent flexibility, applicability and the enormous

properties of Liposomal formulations are expected to remain as the emerging drug delivery resources.

Page 4: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 4

Segmentation of Liposomes Market by Therapeutic Application

Global Liposomal Therapeutic market is segmented by therapeutic area into Antifungal, Anticancer,

Ophthalmic and Other.

Exhibit 2. Segmentation by Therapeutic Application

Therapeutic

Antifungal

Anticancer

Ophthalmic

Other*

© RIT, 2013

*Includes vaccines (Influenza, Hepatitis), Prostaglandins, Antimalarials,

Cardiovascular Diseases, Dermatology, Analgesics

Page 5: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 5

Global Market Analysis

Exhibit 3. Liposomes– Global Market Estimations and Predictions (2005 – 2020) in US$ Billion

Year Value

2005 XX.XX

2006 XX.XX

2007 XX.XX

2008 XX.XX

2009 XX.XX

2010 XX.XX

2011 XX.XX

2012 XX.XX

2013 XX.XX

2014 XX.XX

2015 XX.XX

2016 XX.XX

2017 XX.XX

2018 XX.XX

2019 XX.XX

2020 XX.XX

CAGR % XX.XX

© RIT Figures, 2013

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

US$ Billion

Page 6: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 6

III. MARKET DYNAMICS

Liposomes and Pharmaceuticals

Cosmeceutical and pharmaceutical markets today boast a wide range of topical products that have many

active ingredients. A common ingredient in many topical application creams and lotions are liposomes that

act as a protective mechanism while also moisturizing the skin. These liposomes are nothing but spherical

vesicles that comprise phospholipids having an aqueous core and contain lipophilic or hydrophilic active

ingredients. Depending on their properties, these dermal applications can penetrate into the skin to carry

these actives to the target site where the molecules get released. Liposomes have improved the efficiency

of many such dermal applications by improving their level of penetration into the skin. They were first used

by cosmetic giant Christian Dior in 1986 in a product named Capture. However, today the use of

nanotechnology in cosmetics is under consideration and therefore it is important to understand the

strength of this new delivery technology.

The use of liposomes in pharmaceutical products is largely for Parenteral and therefore systemic

applications. Typical examples of liposomes in pharmaceutical products are Lipofundin™ developed by

Braun Melsungen, Intralipid™ by Kabi Pharmacia and Arikace™ a liposomally encapsulated Amikacin

prescribed for lung disease. The lipid that is generally used to make these liposomes is phsophatidylcholine

that forms a part of the cell membrane and is therefore not hazardous. Liposomal cosmetics that contain

phospholipids with a flexible membrane are made of biodegradable material, for example ROVISOME®.

Liposomes and Nanotechnology

ROVISOME® is a flexible liposome that has unilamellar vesicles of very small size (approximately 50-400 nm)

and comprises more than 80% of soybean phosphatidylcholine and a large amount of linoleic acid as well.

This type of liposomes provides the skin with essential polyunsaturated fatty acids or vitamin F that

facilitate ceramide 1 formation and with choline that forms a component of NMF or natural moisturizing

factor. In an experimental study that was carried out, liposomes also exhibited other properties such as

reduction in wrinkles and also improving the smoothness of the skin. They also exhibited pharmaceutical

properties such as reducing efflorescences in the treatment of acne. In-vivo and ex-vivo studies have also

shown liposomes to have the ability to penetrate the skin. In addition the encapsulation and delivery of

hydrophilic and lipophilic actives of differing molecular sizes increases the bioavailability thereby improving

the effectiveness of the final product that is also inexpensive.

Page 7: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 7

Analysis by Application

Exhibit 4. Liposomal Applications– Global Market Estimations and Predictions (2005 – 2020) for

Therapeutic, Cosmetic and Other in US$ Billion

Year/Application Liposomal Therapeutics Cosmetics Others Total

2005 XX.XX XX.XX XX.XX XX.XX

2006 XX.XX XX.XX XX.XX XX.XX

2007 XX.XX XX.XX XX.XX XX.XX

2008 XX.XX XX.XX XX.XX XX.XX

2009 XX.XX XX.XX XX.XX XX.XX

2010 XX.XX XX.XX XX.XX XX.XX

2011 XX.XX XX.XX XX.XX XX.XX

2012 XX.XX XX.XX XX.XX XX.XX

2013 XX.XX XX.XX XX.XX XX.XX

2014 XX.XX XX.XX XX.XX XX.XX

2015 XX.XX XX.XX XX.XX XX.XX

2016 XX.XX XX.XX XX.XX XX.XX

2017 XX.XX XX.XX XX.XX XX.XX

2018 XX.XX XX.XX XX.XX XX.XX

2019 XX.XX XX.XX XX.XX XX.XX

2020 XX.XX XX.XX XX.XX XX.XX

CAGR % XX.XX XX.XX XX.XX XX.XX

© RIT Figures, 2013

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

US$ Billion

Liposomal Therapeutics Cosmetics Others

Page 8: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 8

Analysis by Liposomal Therapeutic Applications

Exhibit 5. Liposomal Ophthalmic Therapeutics – Global Market Estimations and Predictions (2005 – 2020)

by Geographic Region for North America, Europe, Asia-Pacific, and Rest of World in US$ Million

Year/Region North America Europe Asia-Pacific Rest of World Total

2005 XX.XX XX.XX XX.XX XX.XX XX.XX

2006 XX.XX XX.XX XX.XX XX.XX XX.XX

2007 XX.XX XX.XX XX.XX XX.XX XX.XX

2008 XX.XX XX.XX XX.XX XX.XX XX.XX

2009 XX.XX XX.XX XX.XX XX.XX XX.XX

2010 XX.XX XX.XX XX.XX XX.XX XX.XX

2011 XX.XX XX.XX XX.XX XX.XX XX.XX

2012 XX.XX XX.XX XX.XX XX.XX XX.XX

2013 XX.XX XX.XX XX.XX XX.XX XX.XX

2014 XX.XX XX.XX XX.XX XX.XX XX.XX

2015 XX.XX XX.XX XX.XX XX.XX XX.XX

2016 XX.XX XX.XX XX.XX XX.XX XX.XX

2017 XX.XX XX.XX XX.XX XX.XX XX.XX

2018 XX.XX XX.XX XX.XX XX.XX XX.XX

2019 XX.XX XX.XX XX.XX XX.XX XX.XX

2020 XX.XX XX.XX XX.XX XX.XX XX.XX

CAGR % XX.XX XX.XX XX.XX XX.XX XX.XX

© RIT Figures, 2013

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020

US$ Million

North America Europe Asia-Pacific Rest of World

Page 9: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 9

Pharmaceutical Market Armed with Liposomes to Combat Fungal Infections

Globally , the instances of fungal infections are on the rise , especially in cases of people who are

immunocompromised. Immunocompromised people are incapable of developing a normal immune

response, usually as a result of disease, malnutrition, or immunosuppressive therapy. Also, there is no

decline in the count of AIDS and cancer patients. So the experts in this field are perturbed.

The therapy and diagnosis of fungal infections are implicitly arduous and demanding, especially to those

more liable to opportunistic infections. Opportunistic infection is an infection by a microorganism that

normally does not cause disease but becomes pathogenic when the body's immune system is impaired and

unable to fight off infection.

Till today the sales output of Amphocil is at a slow pace, but Abelcet is the foremost to get certified in the

United States. In November 1995, the FDA certified the drug to be harmless and is capable of causing the

intended effect in curing aspergillosis in patients who cannot withstand or are refractory to amphotericin B.

The initial sale output of company was declared to be $6 million. Market experts were expecting

certifications from FDA for by year 1996 ending for Amphotec and by year 1997 for AmBisome. All the

three drugs are expected to have the same effect as expressed by some experts like Walsh and Edward

Hurwitz, an analyst with Robertson, Stephens & Co., Only the marketing strategy and price elements will be

the determining elements.

Exhibit 6. List of Liposomal Therapeutics

S. No. Product Developer Clearance Details

Country Year Approval Reason

1 AmBisome (liposomal

amphotericin B)

NexStar

Pharmaceuticals, Inc

Ireland 1989 Treatment of refractory

fungal infections

2 Amphocil (amphotericin

B colloidal dispersion)

Sequus

Pharmaceuticals, Inc.,

United

Kingdom

1994 Same indication as first

3 Abelcet (amphotericin B

lipid complex)

The Liposome

Company's

UK 1995 first-line therapy in the

treatment of AIDS-related

cryptoccocal meningitis and

systemic cryptococcosis

More…..

© RIT, 2013

Exhibit 7. List of Global Major Companies

S. No Company Region Website

1 Advanced Biomedical Ltd. UK www.advanced-biomedical.co.uk

2 Arboretum Skincare USA www.arboretum-skincare.com

3 Avanti Polar Lipids, Inc. USA www.avantilipids.com

4 Azaya Therapeutics, Inc. USA www.azayatherapeutics.com

5 BioZone Laboratories, Inc. USA www.biozonelabs.com

6 Luye Pharma Group Ltd. China www.luye.cn

7 SurModics Pharmaceuticals USA www.surmodicspharma.com

More…

© RIT, 2013

Page 10: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 10

LIPOSOMES – THE OUTLOOK

The market for liposomes presents attractive growth opportunities, driven by growing demand for

increasingly effective drugs in the field of pharmaceuticals, and niche applications in other emerging areas.

Liposome drug delivery systems have been instrumental in the formulation of potent drugs to enhance

therapeutics. A majority of liposome formulations are designed to bring down toxicity. It is also in a limited

way formulated enhance accumulation at the target site and rendered useful in several clinical applications.

Presently pharmaceutical products of liposome-based therapeutics arise from a better understanding of

lipid-drug interactions as well as liposome disposition mechanisms. Among these mechanisms are included

the impeding of the fast clearance of liposomes. This is achieved by exercising control over surface

hydration, charge and size. Liposomes are actually lipid vesicles that are derived from self-forming enclosed

lipid bi-layers upon hydration.

Increased protection and elevated efficaciousness are being accomplished for an extensive range of drug

classes. These encompass gene therapeutics, vaccines, antimicrobials, antifungal, antiviral and anti-tumor

agents. The comprehension that is acquired from clinical use of liposome drug delivery systems can

presently be amalgamated for the design of liposomes that are targeted to tissues and cells. This could be

with or without expression of target recognition molecules on liposome membranes.

Continued improvements of bio-membrane sensors and liposome delivery systems that are competent in

the association of other membrane-bound proteins in vivo could allow selective delivery of therapeutic

compounds to chosen intracellular target areas.

As large quantities of stable and cost-effective liposomes are manufactured, many new applications will

surface. The novel applications could be self-healing paints, single tube two-component resins or glues and

water-based paints…..

Page 11: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 11

IV. PRODUCT/TECHNOLOGY RESEARCH

Liposomes are nano size artificial vesicles of spherical shape composed of a bilayer membrane that can be

produced from natural phospholipids and cholesterol. Liposomes are composed of naturally-derived

phospholipids which when combined with water immediately forms a bi-layered sphere. Liposomes contain

a core of aqueous material; lipid spheres that contain no aqueous material are called micelles,

In 1961, Dr Alec D. Bangham produced the first liposomes. He was studying the relationship between blood

clotting and phospholipids. He observed that as soon as phospholipids came into contact with water, they

assumed a spherical structure. Dr. Bangham also deciphered the cause for this transformation. He noticed

that one end of the phospholipid molecule was water soluble, while the other end was not. Therefore,

when water-soluble drugs were added to water, they were enclosed or trapped within the hydrophobic

ends. The reverse was the case when fat-soluble medicaments were brought near phospholipids. Such

drugs were trapped within the phospholipid layers.

Liposomes are artificial vesicles that are made up of concentric bilayers of lipid that are separated by

compartments of water. The bilayer forming lipids are amphiphilic in nature meaning they have a polar

head group that is attached to one or maybe even two hydrophobic hydrocarbon tails. On exposure to an

aqueous medium the hydrophilic heads interact with each other and Vender Waal’s interactions are also

seen between the hydrocarbon chains. They also interact with water called hydrophilic interactions with a

hydrophobic effect that then result in a spontaneous formation of bilayers that are closed.

The size of these spheres is very small, in the order of a nanometer. Liposomes are of various sizes ranging

from those having a diameter of 20nm to others that are visible under a light microscope with a diameter

of 1 µm or bigger and similar in size to living cells. Because of the small size of the phospholipid molecule

and microspheres, they can pass through the epidermis and act as a carrier for the enclosed substances.

Liposomes are also different with respect to their lipid composition and structural organization based upon

which they can be classified into unilamellar, multilamellar and oligolamellar vesicles. Liposomes have been

made so that the solute can be surrounded by the aqueous compartment called polar solute or

alternatively be embedded in the lipid bilayers known as lipophilic or amphiphilic solutes.

Liposomes also comprise small deposits that may contain an antibiotic, antigen, allergen, drug substance or

even a gene. Liposomes are capable of entering the body without causing an immune rejection or

hypersensitivity reaction.

Phospholipids arrange themselves so as to form a membrane having a wall of hydrophilic heads that would

prevent permeation of oil droplets through it. It is also not possible for water to pass through the

membrane due to the presence of lipophilic tails of the liposomes that do not allow passage of water. The

only part of the membrane that allows passage of only certain chemicals into and out of the cell is special

protein molecules that are programmed for the purpose.

The use of liposomes in biological and biochemical research are five-fold. They include:

Lipid-Protein interactions

Membrane dynamics

Page 12: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 12

Delivery systems for biomolecules and small molecules into cells

Membrane related proteins

Regulation of protein function by lipids

Forms of Liposomes

1. Conventional forms of liposomes include

Stabilized natural lecithin (PC) mixtures

Synthetic identical-chain phospholipids

Glycolipid containing liposomes

2. Special forms of liposomes are

Bipolar fatty acid liposomes

Antibody directed liposomes

Methyl/ Methyane liposomes

3. x-linked liposomes

Lipoprotein coated liposomes

Carbohydrate wated liposomes

Multiple encapsulated liposomes

Emulsion compatible liposomes

Conventional liposomes are man-made liposomes that can carry and deliver drugs that can also delay their

elimination by the system. This in turn permits the drugs to stay in the bloodstream for prolonged period of

time. These liposomes when heated to a specific temperature (40ºC to 42ºC), there occurs an opening in

the liposomes thereby permitting its drug to released rapidly in the targeted area.

Exhibit 8. List of Liposome based Drugs in Clinical Trials

Trade Name Indication Company Status

Liposomal alpha-TEA (α-TEA) (cyclosporine) Rejection post lung transplantation, asthma & cancer Alulim Pharma, Inc. Preclinical

Liposomal Cyclosporine A (cyclosporine) Rejection post lung transplantation, asthma & cancer Alulim Pharma, Inc. Preclinical

ATI-0918 (Liposomal encapsulation of

doxorubicin)

Cancer Azaya Therapeutics, Inc. Preclinical

ATI-1123 (Liposomal formulation of

docetaxel)

NSCLC, gastric cancer, pancreatic cancer, and soft-

tissue sarcoma

Azaya Therapeutics, Inc. Phase II

Thermodox (Doxorubicin) Recurrent chest wall breast cancer Celsion Corporation Phase I/II

More…

© RIT Figures, 2013

About RI Technologies

RI Technologies is a premier source of market research on the Biotechnology & Healthcare sector. We

emphasize on factual insights and forecasts with maximum global coverage. RI Technologies is constantly

Page 13: pegylated liposomes | peg liposomes | liposomes research report

RITMIR028: Liposomes – A Market Insight Report, July 2013

© RI Technologies - www.researchimpact.com Sample Page - 13

monitoring the biotechnology & Healthcare industry, tracking market trends, and forecasting industry

based on specialized analysis. The life sciences sector is an ever growing marketplace with emerging

technologies in areas of discovery, design and development.

Research – As Good as the Methodology is!

Gauging Competitive Intelligence

Identifying Key Growth Areas and Opportunities

Understanding Geographic Relevance to Product

Knowing Regional Market Sizes and Growth Opportunities and Restraints

Keeping Tab on Emerging Technologies

Equity Analysis

Tapping New Markets

© COPYRIGHT

The copyright and publication rights to all RI Technologies' reports and other products are the property of

the company. Plagiarism of any kind accounts to violation of copyright laws. Any type of reproduction of

the material without express permission is not allowed. The buyer, under no circumstances, shall license,

resell or repackage, or sell data without prior permission of the company.

DISCLAIMER

RI Technologies sells content in good faith. The company is not liable to the buyer for any implications

arising out of the usage of data for any particular purpose. The company makes no representations or

warranties for the accuracy or completeness of the data. While extreme caution and effort is practiced for

data compilation and presentation, the company does not accept any responsibility for findings in the study

which are a cumulative effort of primary and secondary research resources. The studies do not endorse or

promote any product or company. RI Technologies, its affiliates, partners, distributors, and contractors are

not liable for inaccuracies or incompleteness of the reports. User discretion is recommended for the usage

of the data.